No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC By Ogkologos - March 3, 2026 235 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SONIA study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR This Common Antibiotic May Help Support Immune System in Cancer Patients... December 12, 2019 For Kids with Medulloblastoma, Trial Suggests Radiation Can Be Tailored July 16, 2021 Cancer Rehabilitation Starts at Diagnosis: Part II July 13, 2021 Check Out An All New GreaterGood.Com And Our Renewed Commitment To... September 30, 2019 Load more HOT NEWS Man Pushes Daughter To Safety Before Speeding Car Hits Him Instead:... Most Cases of Venous Thromboembolic Events, Elevated Aminotransferases, and Interstitial Lung... Cancer Research UK thanks Tania Bryer for a decade of fundraising... Significantly Longer PFS with First-line Pembrolizumab for MSI-H/dMMR mCRC
